Background: Glioblastoma multiforme (GBM) is a very aggressive primary central nervous system (CNS) tumor with limited therapeutic options and poor prognosis. This study aimed to analyze the association between single nucleotide polymorphisms (SNPs), including IDH1 rs121913500C > T, IDH2 rs11540478G > A, and EGFR rs1468727C > T, and their association on the risk and overall survival of GBM patients in Jordan.
Methods: Using a case-control study design involving 63 GBM patients and 226 healthy controls was conducted at King Abdullah University Hospital in Jordan. DNA extraction was performed using formalin-fixed and paraffin-embedded tissue for GBM samples and blood samples for controls. SNPs analysis was performed using the Sequenom iPLEX assay sequencing technique. Survival outcomes were assessed using Cox models and hazard ratios (HR), and single-cell RNA (scRNA) analysis was performed from GSE70630.
Results: The study showed a significant association between genotype frequency in GBM cases and controls for specific SNPs, including IDH1 rs121913500C > T, and EGFR rs1468727C > T. The G/G genotype of rs11540478 (IDH2) was associated with better prognostic outcomes in GBM patients. The scRNA analysis demonstrated the differential expression of IDH1, IDH2, and EGFR in GBM, with enrichment in central carbon metabolism in cancer.
Conclusion: Our findings suggest that SNPs, particularly in IDH1 and IDH2 genes and EGFR, may serve as diagnostic and prognostic biomarkers for GBM. While the study underscores the clinical relevance of these genetic variants, further investigations with larger and more diverse populations are essential to validate and extend these associations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333891 | PMC |
| http://dx.doi.org/10.1016/j.heliyon.2024.e35323 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preoperative anemia is associated with prolonged hospital stay and increased facility discharges after glioblastoma resection.
Front Surg
January 2025
Saint Luke's Cancer Institute, Saint Luke's Hospital, Kansas, MO, United States.
Background: Despite numerous operative and non-operative treatment modalities, patients with glioblastoma (GBM) have a dismal prognosis. Identifying predictors of survival and recurrence is an essential strategy for guiding treatment decisions, and existing literature demonstrates associations between hematologic data and clinical outcomes in cancer patients. As such, we provide a novel analysis that examines associations between preoperative hematologic data and postoperative outcomes following GBM resection.
View Article and Find Full Text PDFBrain tumor enhancement prediction from pre-contrast conventional weighted images using synthetic multiparametric mapping and generative artificial intelligence.
Quant Imaging Med Surg
January 2025
Radiology and Nuclear Medicine Department, Erasmus MC, Rotterdam, The Netherlands.
Background: Gadolinium-based contrast agents (GBCAs) are usually employed for glioma diagnosis. However, GBCAs raise safety concerns, lead to patient discomfort and increase costs. Parametric maps offer a potential solution by enabling quantification of subtle tissue changes without GBCAs, but they are not commonly used in clinical practice due to the need for specifically targeted sequences.
View Article and Find Full Text PDFEnhancement of the nontumor component in newly diagnosed glioblastoma as a more accurate predictor of local recurrence location: a multicenter study.
Quant Imaging Med Surg
January 2025
Department of Radiology, Medical Imaging Institute of Tianjin, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Background: Although the spatial heterogeneity of glioblastoma (GBM) can be clearly mapped by the habitats generated by magnetic resonance imaging (MRI), the means to accurately predicting the spatial location of local recurrence (SLLR) remains a significant challenge. The aim of this study was to identify the different degrees enhancement of GBM, including the nontumor component and tumor component, and determine their relationship with SLLR.
Methods: A retrospective analysis was performed from three tertiary medical centers, totaling 728 patients with 109 radiation-induced temporal lobe necrosis (TLN) of nasopharyngeal carcinoma (NPC) and 619 with GBM.
FOLR1 Regulates the Malignant Progression of Glioblastoma through the SRC/ERK1/2 Axis.
Comb Chem High Throughput Screen
January 2025
School of Public Health, Zhengzhou University, No. 100, Science Avenue, High-tech Zone, Zhengzhou, Henan 450001, China.
Background: GBM is an aggressive brain tumor with limited treatment options. Prior research has indicated FOLR1 as a pivotal gene involved in cancer pathogenesis.
Aim: This study aimed to explore the involvement of folate receptor alpha (FOLR1) in glioblastoma (GBM) and evaluate its potential as a therapeutic target.
Genetically Engineered Brain Organoids Recapitulate Spatial and Developmental States of Glioblastoma Progression.
Adv Sci (Weinh)
January 2025
Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8127, St. Louis, MO, 63110, USA.
Glioblastoma (GBM) is an aggressive form of brain cancer that is highly resistant to therapy due to significant intra-tumoral heterogeneity. The lack of robust in vitro models to study early tumor progression has hindered the development of effective therapies. Here, this study develops engineered GBM organoids (eGBOs) harboring GBM subtype-specific oncogenic mutations to investigate the underlying transcriptional regulation of tumor progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!